Skip to content

The Impact of the SCN9A Gene Polymorphism on Postoperative Pain

The Impact of the Single Nucleotide Polymorphisms rs6746030,rs7604448, rs10930214, s7595255 in SCN9A Gene on Postoperative Pain and Analgesic Consumption After Cesarean Section

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02496455
Enrollment
200
Registered
2015-07-14
Start date
2015-08-31
Completion date
2017-11-30
Last updated
2017-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Postoperative, Pregnancy

Keywords

NAV1.7 Voltage-Gated Sodium Channel, pain, postoperative, cesarean section

Brief summary

The purpose of this study to determine the association between postoperative pain after cesarean section and several single nucleotide polymorphisms in SCN9A sodium channels gene.

Detailed description

SCN9A gene encodes an alpha subunit of the voltage-gated sodium channel (Nav1.7) and polymorphisms of this gene are associated with severe pain disorders. The impact of the polymorphisms in SCN9A on postoperative pain and opioid consumption after cesarean section is unclear.

Interventions

PROCEDUREcesarean section

Women in 36 to 40 weeks of pregnancy undergoing cesarean section by Pfannenstiel technique

DRUGOpioid Tramadol

Tramadol will be administered via patient controlled analgesia (PCA) pump in the postoperative period

Sponsors

Tokat Gaziosmanpasa University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* The women aged 18 to 45, * in 36 to 40 weeks of pregnancy * undergoing cesarean section

Exclusion criteria

* History of chronic pain or pain disorders * Psychiatric diseases * Diabetes mellitus * Severe cardiovascular, kidney or liver diseases * Alcohol or drug abuse * Heavy smoker * Unable to use the Patient controlled analgesia (PCA) pump

Design outcomes

Primary

MeasureTime frameDescription
Painup to postoperative 24 hoursThe pain will be evaluated with the visual analog scale

Secondary

MeasureTime frameDescription
Opioid consumptionUp to postoperative 24 hoursThe total amount of the tramadol administered to the patient will be recorded

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026